Overview
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Status:
Terminated
Terminated
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis
Criteria
Inclusion Criteria:- Confirmed diagnosis of multiple myeloma
- Evidence of relapsed or refractory disease
Exclusion Criteria:
- Intracranial disease or epidural disease
- Clinically significant cardiac disease
- Diabetes mellitus